Eurocine Vaccines has signed research and partnership agreement with Redbiotec to develop candidates for vaccines against Herpes Simplex Virus Type 2 (HSV-2).
Under the agreement, Eurocine will receive exclusive international rights to develop, manufacture and market vaccines.
Vaccines will be developed using Redbiotec technology.
The agreement includes both transmitting ribonucleic acid (mRNA) and protein-based technology, its documentation and patents in the field of HSV-2.
Under the deal, Eurocine will monitor and fund all development, production and marketing activities until an external licensing agreement is signed with a third party.
The companies will share the proceeds from any future transfer of licenses or grants to third parties, based on the stage of development of the project at which the transaction with the third party is signed.
In addition, Redbiotec is entitled to remuneration for Eurocine’s net sales of an approved HSV-2 vaccine.
In addition, Eurocine listed the moments for immediate action after the signing of the last transaction.
The companies will plan future developments, including preclinical and clinical studies, documentation, patents and business development, as well as active marketing.
A decision will be made as to which technology to follow, mRNA or a candidate for a protein-based vaccine.
In addition, the potential of the prophylactic HSV-2 vaccine will be analyzed after the development of this therapeutic vaccine and the possible synergies of these vaccines.
Eurocine Vaccines CEO Hans Arvidson said: “I am very pleased to have added this promising candidate to our portfolio, especially given the impressive scientific development of the therapeutic vaccine developed so far by Redbiotec.
“The candidate is fully in line with our portfolio strategy.”
Sexually transmitted disease, HSV-2 is currently mainly treated with antiviral drugs and there is no effective therapeutic vaccine on the market.
The coverage for cell and gene therapy in pharmaceutical technology is maintained by Cytiva.
Editorial content is produced independently and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.